sec filing
FA
NASDAQ · FATE
Fate Therapeutics, Inc.
Healthcare · Biotechnology
$2.06
Up+$0.02 (+0.97%)
Updated Oct 27, 2026, 2:52 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 128M
- P/E ratio
- -0.85
- Dividend yield
- 0.00%
- 52-week range
- $0.95 – $3.23
- Volume
- 1.46M
- Avg. volume
- 2.11M
Price performance · FATE
FATE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
FATE closed at $2.06 after 21 trading sessions, down 13.66% for the selected period.
- Last close
- $2.06
- Period change
- -13.66%
- Period low
- $1.79
- Period high
- $2.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $2.10 | $2.14 | $2.04 | $2.055 | 1.46M |
| Oct 23, 2026 | $2.08 | $2.135 | $2.015 | $2.11 | 1.11M |
| Oct 22, 2026 | $2.07 | $2.11 | $2.035 | $2.09 | 867.18K |
| Oct 21, 2026 | $2.06 | $2.14 | $2.045 | $2.07 | 1.22M |
| Oct 20, 2026 | $1.86 | $2.145 | $1.84 | $2.06 | 1.77M |
| Oct 19, 2026 | $1.79 | $1.90 | $1.75 | $1.86 | 1.68M |
| Oct 16, 2026 | $1.94 | $1.975 | $1.78 | $1.79 | 1.38M |
| Oct 15, 2026 | $1.96 | $1.995 | $1.91 | $1.925 | 1.16M |
| Oct 14, 2026 | $1.95 | $1.99 | $1.89 | $1.94 | 1.67M |
| Oct 13, 2026 | $2.13 | $2.13 | $1.98 | $2.00 | 953.48K |
| Oct 12, 2026 | $2.13 | $2.18 | $2.104 | $2.13 | 616.85K |
| Oct 9, 2026 | $2.13 | $2.275 | $2.10 | $2.18 | 773.47K |
| Oct 8, 2026 | $2.12 | $2.13 | $2.03 | $2.13 | 1.48M |
| Oct 7, 2026 | $2.28 | $2.30 | $2.14 | $2.15 | 863.01K |
| Oct 6, 2026 | $2.43 | $2.49 | $2.285 | $2.29 | 1.14M |
| Oct 5, 2026 | $2.32 | $2.575 | $2.29 | $2.43 | 3.38M |
| Oct 2, 2026 | $2.34 | $2.36 | $2.27 | $2.32 | 658.02K |
| Oct 1, 2026 | $2.37 | $2.39 | $2.285 | $2.30 | 812.98K |
| Sep 30, 2026 | $2.40 | $2.495 | $2.355 | $2.37 | 1.08M |
| Sep 29, 2026 | $2.37 | $2.41 | $2.29 | $2.38 | 1.44M |
| Sep 28, 2026 | $2.30 | $2.42 | $2.27 | $2.38 | 1.16M |
Latest FATE news
The latest Smart Investors Daily articles mentioning FATE.
Stock researchResearch & News · News
Company
Market Activity
Research & News
Loading stock research…

